OBJECTIVE: To study the association of lipoprotein particles with CVD in a subgroup of HIV-infected patients who were enrolled in the Strategies for Management of Anti-Retroviral Therapy (SMART) study. SMART was a trial of intermittent use of ART (drug conservation [DC]) versus continuous of ART (viral suppression [VS]). METHODS: In a nested case-control study, lipoprotein particles (p) by nuclear magnetic resonance were measured at baseline and at the visit prior to the CVD event (latest levels) for 248 patients who had a CVD event and for 480 matched controls. Odds ratios (ORs) were estimated using conditional logistic models. RESULTS: Total, large and small HDL-p, but not VLDL-p nor LDL-p, were significantly and inversely associated with CVD and its major component, non-fatal coronary heart disease. The HDL-p associations with CVD were reduced after adjustment for high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6) and D-dimer. Latest levels of total HDL-p were also significantly inversely associated with CVD; treatment interruption led to decrease of total HDL-p; adjusting for latest HDL-p did not explain the greater risk of CVD that was observed in the DC versus VS group. CONCLUSIONS:Lipoprotein particles, especially lower levels of small and large HDL-p identify HIV-infected patients at increased risk of CVD independent of other CVD risk factors.
RCT Entities:
OBJECTIVE: To study the association of lipoprotein particles with CVD in a subgroup of HIV-infectedpatients who were enrolled in the Strategies for Management of Anti-Retroviral Therapy (SMART) study. SMART was a trial of intermittent use of ART (drug conservation [DC]) versus continuous of ART (viral suppression [VS]). METHODS: In a nested case-control study, lipoprotein particles (p) by nuclear magnetic resonance were measured at baseline and at the visit prior to the CVD event (latest levels) for 248 patients who had a CVD event and for 480 matched controls. Odds ratios (ORs) were estimated using conditional logistic models. RESULTS: Total, large and small HDL-p, but not VLDL-p nor LDL-p, were significantly and inversely associated with CVD and its major component, non-fatal coronary heart disease. The HDL-p associations with CVD were reduced after adjustment for high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6) and D-dimer. Latest levels of total HDL-p were also significantly inversely associated with CVD; treatment interruption led to decrease of total HDL-p; adjusting for latest HDL-p did not explain the greater risk of CVD that was observed in the DC versus VS group. CONCLUSIONS: Lipoprotein particles, especially lower levels of small and large HDL-p identify HIV-infectedpatients at increased risk of CVD independent of other CVD risk factors.
Authors: Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras Journal: Circulation Date: 2008-06-19 Impact factor: 29.690
Authors: Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas Journal: Atherosclerosis Date: 2006-10-02 Impact factor: 5.162
Authors: Sharon A Riddler; Xiuhong Li; James Otvos; Wendy Post; Frank Palella; Lawrence Kingsley; Barbara Visscher; Lisa P Jacobson; A R Sharrett Journal: J Acquir Immune Defic Syndr Date: 2008-07-01 Impact factor: 3.731
Authors: Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal Journal: Arterioscler Thromb Vasc Biol Date: 2002-07-01 Impact factor: 8.311
Authors: Honor Rose; Jennifer Hoy; Ian Woolley; Urbain Tchoua; Michael Bukrinsky; Anthony Dart; Dmitri Sviridov Journal: Atherosclerosis Date: 2007-12-04 Impact factor: 5.162
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Phyllis C Tien; Michael F Schneider; Christopher Cox; Mardge Cohen; Roksana Karim; Jason Lazar; Mary Young; Marshall J Glesby Journal: AIDS Date: 2010-11-27 Impact factor: 4.177
Authors: Peter W Hunt; Elizabeth Sinclair; Benigno Rodriguez; Carey Shive; Brian Clagett; Nicholas Funderburg; Janet Robinson; Yong Huang; Lorrie Epling; Jeffrey N Martin; Steven G Deeks; Curtis L Meinert; Mark L Van Natta; Douglas A Jabs; Michael M Lederman Journal: J Infect Dis Date: 2014-04-21 Impact factor: 5.226
Authors: Jason Baker; Woubeshet Ayenew; Harrison Quick; Katherine Huppler Hullsiek; Russell Tracy; Keith Henry; Daniel Duprez; James D Neaton Journal: J Infect Dis Date: 2010-01-15 Impact factor: 5.226